oncology

Carlsbad – September 08, 2026 -- Tyra Biosciences, Inc. (Nasdaq: TYRA) will disclose initial clinical results from its SURF302 Phase 2 study of oral dabogratinib in intermediate risk non-muscle invasive bladder cancer (IR NMIBC) during a conference call scheduled for September 9, 2026, at 8:00 am ET.

Tyra sets September 9 call to unveil first SURF302 data

The clinical-stage biotech confirmed the call and webcast will present initial efficacy and safety data from the ongoing SURF302 trial, marking the first public disclosure of results for dabogratinib in this bladder cancer indication.

Dabogratinib targets FGFR3-driven tumors as lead pipeline asset

Dabogratinib is Tyra's lead precision medicine candidate, developed as a potential first-in-class selective FGFR3 inhibitor. Beyond IR NMIBC, the company is advancing the drug for low-grade upper tract urothelial cancer (LG-UTUC) and achondroplasia (ACH).

Hong Kong – September 07, 2026 -- Akeso, Inc. (9926.HK) said its bispecific antibody ivonescimab produced a statistically significant and clinically meaningful overall survival benefit versus Merck's pembrolizumab in a pre-specified interim analysis of the Phase III HARMONi-2 trial, as assessed by an Independent Data Monitoring Committee.

Ivonescimab clears key secondary survival endpoint against Keytruda

The HARMONi-2 (AK112-303) study is a randomized, double-blind, multicenter registrational trial testing ivonescimab against pembrolizumab as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 at a TPS of 1% or higher. Detailed interim overall survival data will be presented at an upcoming international medical conference and published in a peer-reviewed journal.